Welcome to our dedicated page for Adaptimmune Therapeutics news (Ticker: ADAPY), a resource for investors and traders seeking the latest updates and insights on Adaptimmune Therapeutics stock.
Adaptimmune Therapeutics plc reports corporate-status and governance developments for its American depositary shares under the symbol ADAPY. Recent company news centers on board and executive leadership changes tied to restructuring, the voluntary delisting of ADSs from Nasdaq, quotation on the OTC Pink Limited Market, and Exchange Act deregistration steps that affect ongoing public-company reporting obligations.
Adaptimmune (OTC Pink: ADAPY) announced Board and executive changes effective November 14, 2025, including the appointment of Chris Hill as CEO while he continues as CFO and Director, and Lawrence Alleva as Chairman.
The company confirmed the voluntary delisting of ADSs from Nasdaq on October 28, 2025 and initiated deregistration under Section 12(b) with Form 25 and Form 15 filings; deregistration is expected around January 26, 2026. Adaptimmune said a transaction with US WorldMeds closed on July 31, 2025 to keep TECELRA available while the company focuses on maximizing value from remaining programs including PRAME and CD70.